Tempus ECG-AF vs EchoGo Pro
AI Verdict
Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your primary objective is to proactively identify and risk-stratify elderly patients (65+) at an elevated risk of developing new-onset atrial fibrillation within the next 12 months. This tool is ideal for leveraging standard 12-lead ECG recordings to support earlier clinical follow-up and intervention for individuals without pre-existing AF or specific cardiac devices.
View Tempus ECG-AF →Choose EchoGo Pro if…
Choose EchoGo Pro if you aim to significantly improve the efficiency and diagnostic accuracy of coronary artery disease (CAD) assessment through automated stress echocardiography analysis. This cloud-based, AI-powered solution is best suited for healthcare systems seeking near-instant, standardized reports and seamless integration with existing imaging workflows, without the need for on-premise software installation.
View EchoGo Pro →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Tempus ECG-AF | EchoGo Pro |
|---|---|---|
| Pricing | Contact vendor | Contact vendor for pricing |
| Deployment | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. | Cloud-based |
| BAA Available | Yes AI-estimated | Yes AI-estimated |
| FDA Status | Yes AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
EchoGo ProEchoGo Pro (Tool B) is a cloud-based SaaS solution that explicitly states it requires no software installation or extensive training, and offers seamless integration with existing clinical workflows (DICOM, HL7) and PACS. This vendor-neutral, no-installation approach generally indicates higher out-of-the-box usability and easier adoption compared to Tempus ECG-AF's (Tool A) description of integration into healthcare facility systems.
Clinical Value
Tempus ECG-AFTempus ECG-AF (Tool A) offers a unique predictive capability, identifying patients at increased risk of developing new-onset atrial fibrillation within 12 months from a standard 12-lead ECG. This proactive identification allows for earlier intervention and follow-up, potentially preventing serious complications like stroke. While EchoGo Pro (Tool B) improves the diagnosis of coronary artery disease, the predictive nature of Tool A for a future event represents a distinct and highly impactful clinical advancement.
Pricing & Value
Tempus ECG-AFBoth tools require contacting the vendor for pricing, limiting transparency. However, Tempus ECG-AF (Tool A) provides specific CMS reimbursement CPT codes (0764T and 0765T) with a clear Medicare rate of $128.90 effective January 1, 2025. EchoGo Pro (Tool B) only mentions reimbursement codes for *related* products without specific rates for EchoGo Pro itself, making Tool A's financial viability clearer for healthcare providers.
Enterprise Readiness
EchoGo ProBoth tools are FDA-cleared, HIPAA compliant, and offer BAAs, demonstrating foundational enterprise readiness. EchoGo Pro (Tool B) stands out with its cloud-based (SaaS) deployment, vendor-neutral system compatibility with any PACS, and seamless integration via DICOM and HL7. This architecture suggests easier scalability and less IT overhead for deployment across diverse enterprise environments compared to Tool A's description of integration into facility systems.
Innovation
Tempus ECG-AFTempus ECG-AF (Tool A) demonstrates significant innovation by leveraging AI on a widely available and inexpensive 12-lead ECG to *predict* the future risk of atrial fibrillation. This shifts the paradigm towards proactive and preventative care from a common diagnostic test. While EchoGo Pro (Tool B) innovates by automating and improving stress echocardiography analysis, Tool A's predictive capability from a simple ECG for a future event is a more novel application of AI in cardiology.
Support & Docs
TieThe provided structured facts for both Tempus ECG-AF (Tool A) and EchoGo Pro (Tool B) do not contain specific information regarding their support services or documentation availability. Without details such as service level agreements, dedicated support portals, or comprehensive documentation libraries, it is not possible to distinguish between the two offerings in this dimension. Both companies are established in the healthcare AI space and are presumed to offer standard enterprise-level support.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Tempus ECG-AF | EchoGo Pro |
|---|---|---|
| Name | Tempus ECG-AF | EchoGo Pro |
| Company | Tempus AI, Inc. | Ultromics |
| Description | FDA-cleared AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up. | FDA-cleared, AI-powered cloud solution by Ultromics that automates stress echocardiography analysis to improve the diagnosis of coronary artery disease, providing near-instant, accurate reports. |
| Primary Use Case | Identifies patients 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within 12 months. | Automates stress echocardiography analysis to improve the diagnosis of coronary artery disease. |
| Target Patient Population (if specified) | Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery. | Not specified |
| Reimbursement Information | CMS reimbursement available (CPT 0764T and CPT 0765T to APC 5734, Medicare rate of $128.90, effective January 1, 2025). | Reimbursement codes available for related EchoGo products (e.g., CPT 0932T for EchoGo Heart Failure, NTAP XXE2X19 for inpatient settings). |
Videos
Demos, reviews, and walkthroughs featuring Tempus ECG-AF and EchoGo Pro.